

3rd edition

Unmet challenges in high-risk hematological malignancies: from benchside to clinical practice

Turin, September 21-22, 2023

Starhotels Majestic

Scientific board:

Marco Ladetto (Alessandria)

Umberto Vitolo (Candiolo-TO)



AUSPICES

- UNIVERSITÀ DEL PIEMONTE ORIENTALE
- ISTITUTO DI CANDIOLO - FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS
- AZIENDA OSPEDALIERA DI ALESSANDRIA SANTI ANTONIO E BIAGIO E CESARE ARRIGO
- UNIVERSITÀ DI TORINO
- FIL - Fondazione Italiana Linfomi
- GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare
- SIE - Società Italiana di Ematologia
- SIES - Società Italiana di Ematologia Sperimentale
- RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D'AOSTA

FACULTY

Ana	Alfonso Piérola	Pamplona, Spain	Georg	Hess	Mainz, Germany
Stephen M.	Ansell	Rochester, USA	Won Seog	Kim	Seoul, Korea
Luca	Arcaini	Pavia, Italy	Shahram	Kordasti	London, UK
Monica	Balzarotti	Rozzano (MI), Italy	Marco	Ladetto	Alessandria, Italy
Nicolas	Boissel	Paris, France	Armando	Lopez-Guillermo	Barcelona, Spain
Benedetto	Bruno	Turin, Italy	Stefano	Luminari	Reggio Emilia, Italy
Alessandro	Busca	Turin, Italy	Federico	Lussana	Bergamo, Italia
Elias	Campo	Barcelona, Spain	Maurizio	Martelli	Rome, Italy
Carmelo	Carlo-Stella	Rozzano (MI), Italy	Massimo	Massaia	Cuneo, Italy
Fabrizio	Carnevale Schianca	Candiolo (TO), Italy	Pau	Montesinos	València, Spain
Bjoern	Chapuy	Berlin, Germany	Talha	Munir	Leeds, UK
Annalisa	Chiappella	Milan, Italy	Grzegorz	Nowakowski	Rochester, USA
Sabina	Chiaretti	Rome, Italy	Bruno	Paiva	Pamplona, Spain
Daniela	Cilloni	Turin, Italy	Stefano A.	Pileri	Milan, Italy
Adalgisa	Condoluci	Bellinzona, Switzerland	Christiane	Pott	Kiel, Germany
Antonio	Cuneo	Ferrara, Italy	Umberto	Ricardi	Turin, Italy
Antonio	Curti	Bologna, Italy	Luigi	Rigacci	Rome, Italy
Hermann	Einsele	Würzburg, Germany	Giulia	Rivoli	Genoa, Italy
Thierry	Facon	Lille, France	Giuseppe	Saglio	Orbassano (TO), Italy
Andres J.M.	Ferreri	Milan, Italy	Valeria	Santini	Florence, Italy
Simone	Ferrero	Turin, Italy	Stephen J.	Schuster	Philadelphia, USA
Robin	Foà	Rome, Italy	Catherine	Thieblemont	Paris, France
Roberto	Freilone	Turin, Italy	Adriano	Venditti	Rome, Italy
Gianluca	Gaidano	Novara, Italy	Carlo	Visco	Verona, Italy
Francesca	Gay	Turin, Italy	Umberto	Vitolo	Candiolo (TO), Italy
Paolo	Ghia	Milan, Italy	Maria Teresa	Voso	Rome, Italy
Guido	Gini	Ancona, Italy	Pier Luigi	Zinzani	Bologna, Italy

09.30 **Welcome and introduction**
M. Ladetto, U. Vitolo and Scientific Authorities

10.00-11.30 HODGKIN LYMPHOMA AND T-CELL LYMPHOMA
Chairmen: U. Ricardi, L. Rigacci

10.00 How I treat high-risk Hodgkin lymphoma in first line
S.M. Ansell

10.20 Novel treatments in relapsed/refractory Hodgkin lymphoma
P.L. Zinzani

10.40 Pathobiology of nodal peripheral T-cell lymphoma
S.A. Pileri

11.00 How I treat high-risk T-cell lymphomas
W.S. Kim

11.20 Panel discussion

11.30-12.45 MANTLE CELL LYMPHOMA

Chairmen: M. Balzarotti, M. Martelli

11.30 Biological identification of high-risk mantle cell lymphoma
E. Campo

11.50 How I treat high-risk mantle cell lymphoma in first line
G. Hess

12.10 How I treat relapsed/refractory mantle cell lymphoma
and new perspectives with CAR-T therapy
C. Visco

12.30 Panel discussion

12.45-13.45 *Lunch*

13.45-15.00 LARGE B-CELL LYMPHOMA

Chairmen: A. Chiappella, A.J.M. Ferreri

13.45 Biological stratification of LBCL: are we ready to use it to tailor the therapy?
B. Chapuy

14.05 How I treat high-risk LBCL in first line
G. Nowakowski

14.25 Novel immunotherapies in relapsed/refractory DLBCL
C. Carlo-Stella

14.45 Panel discussion

15.00-15.30 LECTURE I

Chairman: *U. Vitolo*

**Emerging immunotherapy in B-cell lymphomas:
the role of bispecific antibodies**

C. Thieblemont

15.30-17.00 INDOLENT LYMPHOMA

Chairmen: *G. Gini, S. Luminari*

15.30 Biological of high-risk follicular lymphoma
C. Pott

15.50 How I treat high-risk follicular lymphoma
S. Ferrero

16.10 How I treat high-risk relapsed/refractory follicular lymphoma
A. Lopez-Guillermo

16.30 How I identify and treat high-risk marginal zone lymphoma
L. Arcaini

16.50 Panel discussion

17.00-17.30 LECTURE II

Chairman: *M. Ladetto*

**Potential opportunities to overcome resistance to CAR-T therapy
in diffuse large B-cell lymphoma**

S.J. Schuster

17.30-18.45 CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: *A. Cuneo, M. Massaia*

17.30 Biology of high-risk CLL
A. Condoluci

17.50 How I treat high-risk CLL in 2023
P. Ghia

18.10 How I treat high-risk relapsed/refractory CLL
T. Munir

18.30-18.45 Panel Discussion

08.30-09.45 MULTIPLE MYELOMA

Chairmen: B. Bruno, R. Freilone

08.30 Biology of high-risk multiple myeloma or the role of minimal residual disease in multiple myeloma
B. Paiva

08.50 How I treat young high-risk multiple myeloma patients
F. Gay

09.10 The challenging treatment of elderly multiple myeloma patients
T. Facon

09.30 Panel discussion

09.45-10.15 LECTURE III

Chairman: B. Bruno

CAR-T in multiple myeloma: therapeutic and timing
H. Einsele

10.15-11.30 ACUTE LYMPHOBLASTIC LEUKEMIA

Chairmen: A. Busca, F. Carnevale Schianca

10.15 Biology of high-risk ALL
S. Chiaretti

10.35 Modern approaches as first line treatment of young adults and elderly patients with acute lymphoblastic leukemia
N. Boissel

10.55 CAR-T in adult ALL
F. Lussana

11.15 Panel discussion

11.30-12.00 LECTURE IV

Chairman: R. Foà

**Worldwide disparity of access to clinical trials
and novel treatments in clinical practice**

G. Gaidano

12.00-13.10 MYELODISPLASTIC SYNDROME

Chairmen: D. Cilloni, V. Santini

12.00 The immune system in MDS: a friend or an enemy?
S. Kordasti

12.20 New approaches for treatment of MDS
A. Alfonso Piérola

12.40 Role of transplantation in high-risk MDS
G. Rivoli

13.00 Panel discussion

13.10-14.10 Lunch

14.10-15.40 ACUTE MYELOBLASTIC LEUKEMIA

Chairmen: G. Saglio, A. Venditti

14.10 Therapy related AML
M.T. Voso

14.30 Treatment of high-risk cytogenetic AML
P. Montesinos

14.50 Immunotherapy in AML and BPDCN
A. Curti

15.10 Panel discussion

15.30-15.40 Closing remarks

M. Ladetto, U. Vitolo

With an unrestricted educational grant of:



abbvie

 Bristol Myers Squibb™

janssen  Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

 MENARINI Stemline

GENERAL INFORMATION

REGISTRATION

Registration is available at www.ercongressi.it - section "I nostri congressi/anno 2023"
The registration fee includes: conference kit, participation in the scientific sessions, certificate of attendance, coffee break, lunch, slides of the meeting.

MEETING VENUE Starhotels Majestic

Corso Vittorio Emanuele II, 54
10123 Torino, Italy
Tel. +39 011 539153

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-376685
- No. 9,8 CME credits for Physicians (Haematology, Oncology, Internal Medicine) and Biologists
- Educational objective: "linee guida-protocolli-procedure"

OFFICIAL LANGUAGE

English

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions.
A certificate will be given to all participants at the end of the meeting.

SCIENTIFIC BOARD

Marco Ladetto MD

Associate Professor in Haematology
University of Eastern Piedmont Amedeo Avogadro
S.S. Antonio and Biagio and Cesaro Arrigo Hospital
Via Venezia, 16 - 15121 Alessandria, Italy

Umberto Vitolo MD

Hematology Consultant
Candiolo Cancer Institute - FPO-IRCCS
Strada Provinciale, 142 - 10060 Candiolo (TO), Italy

SCIENTIFIC COMMITTEE

Prof. Benedetto Bruno - Torino
Prof. Gianluca Gaidano - Novara
Prof. Massimo Massaia - Cuneo
Prof.ssa Valeria Santini - Firenze
Prof. Adriano Venditti - Roma

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it